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Abstract
Background: The role of adjuvant chemoradiation therapy for ampullary carcinoma is unknown. Previous literature
suggests that certain populations with high risk factors for recurrence may benefit from adjuvant chemoradiation.
We combined the experience of two institutions to better delineate which patients may benefit from adjuvant
chemoradiation.
Methods: Patients who underwent curative surgery for ampullary carcinoma at the Johns Hopkins Hospital (n =
290; 1992-2007) and at the Mayo Clinic (n = 130; 1977-2005) were reviewed. Patients with <60 days of follow-up,
metastatic disease at surgery, or insufficient pathologic data were excluded. The final combined study consisted of
186 patients (n = 104 Johns Hopkins, n = 82 Mayo). Most patients received 5-FU based chemoradiation with
conformal radiation. Cox proportional hazards models were used for survival analysis.
Results: Median overall-survival was 39.9 months with 2- and 5-year survival rates of 62.4% and 39.1%. On
univariate analysis, adverse prognostic factors for overall survival included T3/T4 stage disease (RR = 1.86, p =
0.002), node positive status (RR = 3.18, p < 0.001), and poor histological grade (RR = 1.69, p = 0.011). Patients who
received adjuvant chemoradiation (n = 66) vs. surgery alone (n = 120) showed a higher rate of T3/T4 stage disease
(57.6% vs. 30.8%, P < 0.001), lymph node involvement (72.7% vs. 30.0%, P < 0.001), and close or positive margins
(4.6% vs. 0.0%, P = 0.019). Five year survival rates among node negative and node positive patients were 58.7%
and 18.4% respectively. When compared with surgery alone, use of adjuvant chemoradiation improved survival
among node positive patients (mOS 32.1 vs. 15.7 mos, 5 yr OS: 27.5% vs. 5.9%; RR = 0.47, P = 0.004). After adjusting
for adverse prognostic factors on multivariate analysis, patients treated with adjuvant chemoradiation
demonstrated a significant survival benefit (RR = 0.40, P < 0.001). Disease relapse occurred in 37.1% of all patients,
most commonly metastatic disease in the liver or peritoneum.
Conclusions: Node-positive patients with resected ampullary adenocarcinoma may benefit from 5-FU based
adjuvant chemoradiation. Since a significant proportion of patients develop metastatic disease, there is a need for
more effective systemic treatment.
Keywords: ampullary, carcinoma, adjuvant, chemoradiation, resectable
* Correspondence: jherma15@jhmi.edu
1Department of Radiation Oncology, Johns Hopkins University School of
Medicine, Baltimore, MD, USA
Full list of author information is available at the end of the article
Narang et al. Radiation Oncology 2011, 6:126
http://www.ro-journal.com/content/6/1/126
© 2011 Narang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
Although carcinoma of the ampulla of Vater is a rare
malignancy with an overall incidence of 6 in 1 million, it
is the second most common periampullary cancer, com-
prising 6-20% of malignancies in this region [1-3]. Com-
pared to pancreatic adenocarcinoma, ampullary cancer is
associated with a higher likelihood of resectability and a
more favorable prognosis. Whereas patients with resect-
able pancreatic adenocarcinoma show a 5-year survival of
only 20%, most retrospective reviews of ampullary cancer
over the past two decades have reported 5-year survival
between 30-40% [4-11]. The earlier appearance of
obstructive symptoms, more favorable histology, and a
decreased inclination for lymphatic or perineural inva-
sion have all been cited as potential explanations for the
better outcomes with ampullary carcinoma [12].
Pancreaticoduodenectomy (PD) remains the only pos-
sible curative treatment for patients with pancreatic or
a m p u l l a r yc a n c e r ,b u tt h er o l eo fa d j u v a n tt h e r a p y
remains controversial. In the United States, postopera-
tive adjuvant chemoradiation (CRT) has been used for
pancreatic cancer based on evidence suggesting
improved survival [4,13,14]. Whether these results can
be extrapolated to resected ampullary carcinoma has
been an area of active debate. A 1999 randomized con-
trolled trial by the European Organization for Research
and Treatment of Cancer (EORTC) examined post-
operative 5-fluorouracil (5-FU) based CRT in patients
with pancreatic head or other periampullary malignan-
cies. This study demonstrated no survival benefit in
patients with periampullary cancer at 2 or 5 years, but
the number of patients with ampullary carcinoma was
small, most of whom had favorable prognostic factors
[14]. More recently, a retrospective review from the MD
Anderson Cancer Center showed a borderline significant
improvement in survival with CRT in a subset of
patients with advanced tumor stage (T3/T4), while a
study from the Mayo Clinic found a survival benefit in
patients with pathologic lymph node involvement
[15,16]. A third review from the Johns Hopkins Hospital
(JHH) also suggested a potential survival benefit from
CRT in patients with resected ampullary carcinoma who
had lymph node involvement, although this finding was
not statistically significant (p = 0.092) [17]. While these
studies indicate that certain subsets of patients with
ampullary carcinoma may benefit from postoperative
CRT, they are limited by the small number of patients
analyzed. In the present study, we combine the experi-
ence of two of the aforementioned institutions, namely
the Johns Hopkins Hospital and the Mayo Clinic, to
compare surgery followed by modern conformal 5-FU
based adjuvant CRT with surgery alone for patients with
resectable carcinoma of the ampulla of Vater.
Methods
Study design and participants
The study was approved by the institutional review
boards of the Mayo Clinic, Rochester, MN, and the
J o h n sH o p k i n sH o s p i t a l ,B a l t i m o r e ,M D .T h es t u d y
cohort was drawn from all patients who underwent
curative surgery for ampullary carcinoma at the Johns
Hopkins Hospital between 1992 and 2007 (n = 290, pro-
spectively collected) and the Mayo Clinic from 1977 to
2005 (n = 130, retrospectively collected). Cancer of the
ampulla of Vater was defined as adenocarcinoma
directly centered on or associated with an in situ carci-
noma of the ampulla, papilla, or both, as evidenced by
review of the final pathology report. Patients with can-
cers arising from the duodenum, pancreatic head, or
common bile duct were not eligible. Patients who were
referred to outside institutions for adjuvant therapy or
follow-up care were excluded because information
regarding the details of their outcomes or whether they
received adjuvant treatment was unavailable (n = 156).
Individuals who died within 60 days of surgery (n = 6),
had less than 60 days of follow-up (n = 6), or had evi-
dence of metastatic disease at surgery (n = 11) were
excluded as well. Those missing information on T-stage,
tumor size, margin status, node status, or histologic
grade (n = 55) were also not analyzed. The final study
population contained 186 patients (n = 104 JHH, n = 82
Mayo).
All patients received preoperative staging by one or
more of the following modalities: abdominal and pelvic-
computed tomography (CT), endoscopic retrograde cho-
langiopancreatography (ERCP), endoscopic ultrasonogra-
phy (EUS), and percutaneous transhepatic
cholangiography or percutaneous biliary drainage (PTC/
PBD). The majority of patients (77%) received both CT
and ERCP. Laboratory tests included a full blood count,
serum electrolytes, creatinine, urea, liver transaminases,
alkaline phosphatase, total bilirubin, carcinoembryonic
antigen (CEA), and carbohydrate antigen 19-9 (CA19-9).
Patient demographic and pathologic data are outlined
in Table 1. Of the 186 patients in the study, 109 (59%)
were male. Median age was 68 years (range 29-90
years). Pathologic data is limited to those variables
potentially conferring poor prognosis, including T-stage,
tumor size, lymph node status, histologic grade, and
margin status.
Surgery
Patients underwent either a pylorus-preserving or classic
pancreaticoduodenectomy (PD). A pylorus-preserving
PD included resection of the head and uncinate process
of the pancreas, distal bile duct, all but the most proxi-
mal duodenum, and gallbladder, when present. In a
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At JHH, 82.5% of patients underwent a pylorus-preser-
ving PD, while these data were unavailable for patients
treated at the Mayo Clinic. All pathology specimens
were reviewed by either a pathologist at JHH or cen-
trally at the Mayo Clinic, and patients were restaged
according to American Joint Committee on Cancer
(AJCC) guidelines, sixth edition. Pathologic data regard-
ing T stage, tumor size, histologic grade, lymph node
involvement, lymphovascular invasion, perineural inva-
sion, and surgical margins were recorded. Lymph nodes
were considered positive if the resection specimen con-
tained metastatic carcinoma in any of the lymph nodes,
whether they were involved by direct extension or con-
tiguous with the primary tumor. At the Mayo Clinic,
margin status was determined by the presence of carci-
noma at the final pancreatic neck, uncinate process, bile
duct, duodenal, or retroperitoneal soft tissue margin. At
JHH, resection margins were considered positive if the
carcinoma was close to (within 1 mm) or present at
these margins.
Chemoradiation regimen
Of the 186 patients in this study, 120 (64.5%) received
surgery alone, while 66 (35.5%) were given adjuvant
CRT. In patients receiving adjuvant therapy, radiation
treatments were administered with a 3-field coplanar
approach (7.6%), 4-field coplanar approach (78.8%), 5-
field non-coplanar approach (3.0%), or intensity modu-
lated radiation therapy (IMRT, 10.6%). A total of 45 Gy
was generally delivered to the ampullary tumor bed
(based on preoperative images), surgical anastomoses
(hepatojejunostomy, pancreaticojejunostomy) and adja-
cent regional lymph nodes (proximal celiac and superior
mesenteric). Additional radiation (5-15 Gy) was admi-
nistered to the tumor bed/area of involved margins and
anastomoses paying careful attention to the dose to the
small bowel. The median total dose was 50.4 Gy (range
Table 1 Baseline Characteristics between Treatment Groups
Observation Only
N = 120
Adjuvant Chemoradiation (CRT) Therapy
N=6 6
P-Value
DEMOGRAPHIC
Age at Surgery (yr)
Mean, (SD*) 68.9 (11.6) 62.0 (10.8) <0.001
Median (Range) 71.3 (28.7-90.3) 63.3 (29.3-81.5)
Gender
Male, No. (%) 66 (55.0) 43 (65.2) 0.179
Institution
Mayo Clinic 63 (52.5) 19 (28.8) 0.002
Johns Hopkins Hospital (JHH) 57 (47.5) 47 (71.2)
TUMOR CHARACTERISTCS
T Stage
1 37 (30.8) 8 (12.1) 0.002
2 46 (38.3) 20 (30.3)
3 33 (27.5) 34 (51.5)
4 4 (3.3) 4 (6.1)
Tumor Diameter
< 3 cm 81 (67.5) 39 (59.1) 0.251
≥ 3 cm 39 (32.5) 27 (40.9)
Nodal Status
N0 84 (70.0) 18 (27.3) <0.001
N1 36 (30.0) 48 (72.3)
Histologic Grading
1 8 (6.7) 0 (0.0) 0.053
2 52 (43.3) 25 (37.9)
3 60 (50.0) 41 (62.1)
Surgical Margins
Positive 0 (0.0) 3 (4.6) 0.019
Negative 120 (100.0) 63 (95.4)
*SD = standard deviation
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fractions except for 7 patients (10.6%) who underwent a
two week planned break in therapy as part of a treat-
ment protocol investigating split-course chemoradiation.
In this protocol, patients received two weeks of 5-fluor-
ouracil based chemoradiation, a two week treatment
break, and two additional weeks of 5-fluorouracil based
chemoradiation, followed by 5-fluorouracil based main-
tenance chemotherapy. No patient received neoadjuvant
or intraoperative radiation. Concurrent chemotherapy
most commonly consisted of 5-fluorouracil (95.5%),
although three patients (4.5%) received gemcitabine.
Maintenance chemotherapy was given to 37.9% of
patients in the form of single-agent 5-fluorouracil
(15.2%), single-agent gemcitabine (19.7%), or combina-
tion gemcitabine with either cisplatin/erlotinib (1.5%) or
capecitabine (1.5%). All patients who received mainte-
nance chemotherapy were treated at JHH. Note that
patients were not excluded from our analysis based on
the concurrent or maintenance chemotherapeutic agents
that were administered given the lack of clear evidence
supporting a specific regimen. None of the patients in
this study were treated with adjuvant chemotherapy
alone.
Statistical Analysis
Statistical analysis was performed using STATA, version
9 (Stata, College Station, TX). Summary statistics for
continuous and dichotomous variables are provided. In
constructing dichotomous variables, thresholds were
defined in accordance with the literature [15-18]. The
distribution of prognostic variables between treatment
groups was compared using Pearson’s chi-squared test.
The primary outcome variable was overall survival (OS),
defined as the time from surgical resection to death.
Survival time was censored at date of last follow up if
death had not occurred. Univariate analysis was con-
ducted using the log-rank test to examine risk factors
and associations with mortality. Median OS was esti-
mated within each risk group and by adjuvant treat-
ment. The proportion of individuals surviving up to 2
and 5 years was calculated using life tables and stratified
by treatment group to assess for a significant difference
using the log-rank test. Proportional hazards models
were used to examine the association of adjuvant treat-
ment, baseline patient characteristics, and pathologic
data with mortality. To explore the independent associa-
tion of adjuvant therapy and OS, multivariate analysis
was performed, adjusting for possible confounders,
namely age, sex, institution, tumor stage, tumor size,
lymph node status, and histologic differentiation. Margin
status was not included in multivariate analysis due to a
paucity of patients with close or positive margins (n =
3). Survival curves were estimated with Kaplan-Meier
techniques.
Results
A tt h et i m eo fa n a l y s i s ,8 2p a tients (44.1%) were still
alive while 104 patients (55.9%) had died. Progression of
disease was the cause of death for 58 patients (55.2%),
while the remaining 46 deaths (44.8%) were from
unknown or other causes. Median follow-up time for
surviving patients was 31.7 months (range 2.0 - 160.1
months).
As displayed in Table 1, when compared with patients
who were treated with surgery alone, those patients who
received adjuvant CRT were significantly younger (62.0
vs. 68.9, p < 0.001), were more likely from JHH (71.2%
vs. 47.5%, p = 0.002), had more advanced T-stage (T3/
T4: 57.6% vs. 30.8%, p = 0.002), and showed more fre-
quent pathologic lymph node involvement (72.3% vs.
30.0%, p < 0.001). Patients in the CRT group also more
frequently had close or positive surgical margins (4.6%
vs. 0.0%, p = 0.019), although only three patients in the
entire sample had close or positive margins, all of whom
were given CRT. Histologic grade, while not significantly
different between treatment groups, did show a trend
towards poorer differentiation amongst patients given
CRT (grade 3: 62.1% vs. 50.0%, p = 0.053). Neither
tumor size nor gender was associated with the type of
treatment that the patient received. Additionally, when
patient demographics and tumor characteristics were
stratified by institution, there was no significant differ-
ence between the JHH and Mayo cohorts for any of
these factors (results not shown).
Median overall survival (mOS) for all patients was
39.9 months (95% CI: 29.5 - 54.7 months) with a 2-year
and 5-year survival of 62.4% and 39.1%, respectively. As
displayed in Table 2, on univariate analysis, lymph node
involvement had the strongest association with
decreased overall survival (mOS: 23.0 vs. 79.4 months,
RR 2.11 - 4.78, p < 0.001). Advanced T-stage and poor
histologic differentiation were also significantly asso-
ciated with poor prognosis. Specifically, tumors classified
as T3/T4 showed significantly worse overall survival
compared with T1/T2 disease (mOS: 27.0 vs. 55.4
months, RR 1.26 - 2.75, p = 0.002), as did grade 3 his-
tology when compared with grade 1 or 2 disease (mOS:
32.1 vs. 60.0 months, RR 1.13 - 2.53, p = 0.011). Age,
gender, institution, tumor size, and margin status were
not predictive of overall survival. Furthermore, as illu-
strated in Figure 1, adjuvant treatment with CRT was
not significantly associated with overall survival when
compared with surgery alone (median survival 39.9 vs.
40.1 months, RR 0.64 - 1.43, p = 0.839) using univariate
analysis. As shown in Table 3, when patients were
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ment type was compared within each subgroup, the
only patients who showed a significant difference in
median survival between adjuvant CRT and surgery
alone were those with pathologic lymph node involve-
ment (mOS: 32.1 vs. 15.7 months, p = 0.004). In node-
positive patients, adjuvant CRT resulted in a 5-year sur-
vival of 27.5%, while surgery alone led to a 5-year rate
of only 5.9%. Figure 2 compares the survival curves by
treatment type for node-positive patients. Median survi-
val was also higher in node negative patients receiving
adjuvant CRT (mOS: 103.2 vs. 61.6 months), but the dif-
ference was not statistically significant (p = 0.122).
As displayed in Table 4, on multivariate analysis, adju-
vant CRT was significantly associated with improved
overall survival (RR 0.25 - 0.67, p < 0.001), when
adjusted for age, gender, institution, T-stage, tumor size,
node status, and grade. Additionally, lymph node invol-
vement was the only other variable associated with
overall survival on multivariate analysis, with node posi-
tive patients experiencing significantly increased risk of
death (RR 2.50 - 7.17, p < 0.001).
Of the 66 patients who underwent adjuvant CRT, 41
(62.1%) experienced some form of toxicity during therapy.
The most common toxicities reported were nausea
(25.8%), diarrhea (16.7%), weight loss (9.1%), fatigue
(9.1%), and epigastric pain (7.6%). While side effects
tended to be mild in nature, treatment-related toxicity did
lead to an interruption of therapy in 8 patients (12.1%).
Grade 3 toxicities were reported in two patients from the
Mayo Clinic who suffered from myelosuppression and
sepsis respectively. The grade of toxicity for patients trea-
ted at JHH was unavailable, although no patient from JHH
was hospitalized for radiation-associated toxicity. There
were no known treatment related deaths.
Sixty-nine patients (37.1%) experienced a recurrence
by the end of follow-up. The most common pattern of
initial recurrence was distant metastasis without local
Table 2 Associations of Overall Survival with Patient Tumor and Treatment Characteristics
No. (%) 2-Year Survival, % 5-year Survival, % Median Survival, months Univariate RR (95% CI) P-value
Age, yrs
< 75 137 (73.7) 66.5 41.2 40.6 1.00 0.281
≥ 75 49 (26.3) 66.7 32.5 35.5 1.27 (0.82 - 1.98)
Gender
Female 77 (41.4) 67.4 37.4 39.9 1.00 0.954
Male 109 (58.6) 66.0 40.4 36.5 0.99 (0.67 - 1.47)
Institution
Mayo Clinic 82 (44.1) 68.6 39.9 40.6 1.00 0.350
JHH 104 (55.9) 64.8 38.9 36.9 1.20 (0.81 - 1.78)
T stage
1/2 111 (59.7) 75.0 46.3 55.4 1.00 0.002
3/4 75 (40.3) 54.1 28.1 27.0 1.86 (1.26 - 2.75)
Tumor Size
≤ 3 cm 120 (64.5) 72.5 39.3 40.1 1.00 0.838
> 3 cm 66 (35.5) 56.5 38.3 35.5 1.04 (0.70 - 1.55)
Node Status
Negative 102 (54.8) 84.1 58.7 79.4 1.00 <0.001
Positive 84 (45.2) 47.2 18.4 23.0 3.18 (2.11 - 4.78)
Histology
Grade 1/2 85 (45.7) 75.8 49.9 60.0 1.00 0.011
Grade 3 101 (54.3) 59.1 30.6 32.1 1.69 (1.13 - 2.53)
Margin Status
Negative 183 (98.4) 66.6 39.3 39.9 1.00 0.493
Positive 3 (1.6) 33.3 0.0 33.3 1.49 (0.47 - 4.72)
Adjuvant Treatment
None 120 (64.5) 67.3 37.2 40.1 1.00 0.839
CRT* 66 (35.5) 65.3 42.1 39.9 0.96 (0.64 - 1.43)
*CRT = chemoradiation
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patients (7.0%) had both local and metastatic disease at
initial relapse. Only 7 patients (3.8%) presented with
local recurrence without evidence of metastatic spread,
of which 6 had not been given adjuvant therapy. The
distribution in patterns of initial recurrence between
treatment groups is summarized in Table 5. Overall, the
liver was the most common site of metastasis, with
24.7% of all patients and 36.5% of those patients who
died harboring disease in the liver. The peritoneum was
the second most common site of metastasis, present in
5.9% of all patients and 9.5% among those patients who
died. Lung metastases were found in 4.8% of all patients
and 6.7% of patients who died, making it the third most
common site of distant spread.
Discussion
This combined series of patients with ampullary carci-
noma represents the largest study to date that demon-
strates an overall survival benefit in patients receiving
adjuvant chemoradiation following surgical resection
when controlling for adverse prognostic factors. After
adjusting for institution, patient demographics such as
age and gender, and disease characteristics such as
tumor stage, tumor size, nodal involvement, and histol-
ogy, patients treated with adjuvant CRT experienced
enhanced survival (HR = 0.41, 95% CI: 0.25-0.67, p <
0.001). This series also confirms improved outcomes in
patients with ampullary carcinoma when compared with
pancreatic cancer, with a median survival of 39.9
months and two and five-year survival rates of 62.4%
and 39.1% respectively.
Pancreaticoduodenectomy is the preferred surgical
approach for carcinoma of the ampulla of Vater that is
amenable to resection [19]. However, similar to pancrea-
tic cancer, the role of post-operative adjuvant therapy
remains undefined. While prognosis for resectable
ampullary carcinoma is considerably better than for
pancreatic cancer, patients with node positive disease
have poor survival and appear to benefit from adjuvant
therapy [20,21]. A number of reports, mostly consisting
of single institution series, have established adverse
prognostic factors, including extent of local invasion,
status of surgical margins, presence of nodal metastasis,
and histologic grade, all of which predict for overall sur-
vival as well as local and distant disease [5-9,22-29]. In
these cohorts, nodal involvement has been a particularly
strong predictor of poor outcomes, with 5-year survival
rates following PD ranging from 64-80% in patients with
node-negative disease and 17-50% in patients with
node-positive disease. A more recent population-based
analysis of roughly 4,000 patients with ampullary carci-
noma was conducted using the National Cancer Insti-
tute’s Surveillance, Epidemiology, and End Results
database [30]. Outcomes were slightly worse than the
aforementioned series from specialized cancer centers
but were highly dependent on nodal metastasis (5 year
survival: 47.6% vs. 21.0%).
High rates of relapse along with identification of
adverse prognostic factors have led to exploration of
adjuvant chemoradiation for “high risk” ampullary carci-
noma, although the literature in this area remains
sparse. Willett et al. first reported a trend towards
improved local control with no improvement in overall
survival when adjuvant 5-FU based chemoradiation was
given to a small cohort of patients with high risk fea-
tures, defined as invasion of the pancreas, nodal metas-
tasis, positive margins, or poor histology [31]. A
subsequent review by Mehta et al. reported a favorable
3-year actuarial survival rate of 44% using adjuvant 5-
FU based chemoradiation in patients with large tumor
size, nodal involvement, positive surgical margins, poor
histology, or neurovascular invasion [32]. Similarly, Lee
et al. achieved superior disease-free survival in patients
with advanced tumor stage (T3/T4) or positive nodes
receiving adjuvant chemoradiation [33]. On multivariate
analysis, adjuvant therapy was also a significantly favor-
able factor for the entire cohort (HR: 0.16, p = 0.030).
However, less than twenty patients received adjuvant
therapy in each of these studies, making it difficult to
derive convincing conclusions.
More recently, three retrospective studies from institu-
tions that treat high volumes of periampullary malignan-
cies reviewed their experience with adjuvant CRT for
ampullary carcinoma. Krishnan et al. examined 96
patients, 54 of whom had received adjuvant CRT
Figure 1 Survival following pancreaticoduodenectomy
stratified by type of adjuvant therapy. Kaplan-Meier curves
comparing overall survival between patients who received adjuvant
chemoradiation (n = 66) and those treated with surgery alone (n =
120). Adjuvant therapy was not significantly associated with
improved overall survival (p = 0.839) on univariate analysis.
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dose of 45 Gy or postoperative radiation to a median
dose of 50.4 Gy, with concurrent 5-FU or capecitabine
[15]. Patients with advanced T-stage (T3/T4) who were
treated with CRT showed a borderline significant
increase in survival (mOS: 35.2 vs. 16.5 months, p =
0.06). Similarly, a JHH review of 111 patients identified
a trend towards improved survival with adjuvant CRT
among those patients with nodal metastasis (mOS: 30.0
vs. 21.6 months, p = 0.092) [17]. Postoperative therapy
in this study consisted of a median radiation dose of
50.4 to the tumor bed and regional nodes with concur-
rent 5-FU or capecitabine. Furthermore, a statistically
significant difference in survival among patients with
lymph node involvement treated with adjuvant CRT was
found in a previous study from the Mayo Clinic (mOS:
3.4 vs. 1.6 years, p = 0.02) [16]. Note, however, that in
none of these studies was adjuvant CRT associated with
increased survival on multivariate analysis.
In the present series, adjuvant therapy was not found
on univariate analysis to be associated with increased
Table 3 Survival between Treatment Groups by Patient, Tumor, and Treatment Characteristics
No. of Patients, (%) Overall Survival, Median, mo 5-year Survival, Percent
Observation Adjuvant CRT Observation Adjuvant CRT P-value Observation Adjuvant CRT
ALL PATIENTS 120 (64.5) 66 (35.5) 39.9 40.1 0.839 37.2 42.1
Age, yrs
< 75 79 (57.7) 58 (42.3) 41.3 40.6 0.913 37.9 45.9
≥ 75 41 (83.7) 8 (16.3) 35.5 33.3 0.939 36.0 25.0
Gender
Female 54 (70.1) 23 (20.9) 42.7 32.1 0.162 40.8 29.3
Male 66 (60.6) 43 (39.4) 32.2 46.0 0.238 33.9 48.4
Institution
Mayo 63 (76.8) 19 (23.2) 38.2 62.4 0.599 35.5 51.3
Hopkins 57 (54.8) 47 (45.2) 41.7 36.5 0.890 40.0 37.0
Histology
Grade 1/2 60 (70.6) 25 (29.4) 53.6 62.2 0.328 47.1 56.6
Grade 3 60 (59.4) 41 (40.6) 34.9 27.1 0.985 27.5 34.1
Node
Negative 84 (82.4) 18 (17.7) 61.6 103.2 0.122 52.4 87.1
Positive 36 (42.9) 48 (57.1) 15.7 32.1 0.004 5.9 27.5
Tumor Stage
T1/T2 83 (74.8) 28 (25.2) 41.3 87.5 0.172 41.7 56.8
T3/T4 37 (49.3) 38 (50.7) 27.0 25.0 0.873 27.5 28.7
Tumor Size
≤ 3 cm 81 (67.5) 39 (32.5) 41.3 36.5 0.797 38.8 40.0
> 3 cm 39 (59.1) 27 (40.9) 27.0 40.6 0.496 33.9 44.0
Margin status
Negative 120 (65.6) 63 (34.4) 40.1 39.9 0.754 37.2 42.7
Positive 0 (0.0) 3 (100.0) N/A 33.3 N/A N/A 33.3
*CRT = chemoradiation
Figure 2 Survival following pancreaticoduodenectomy in node
positive patients stratified by type of adjuvant therapy. Kaplan-
Meier curves comparing overall survival amongst node-positive
patients between patients who received adjuvant chemoradiation (n
= 48) and those treated with surgery alone (n = 36). In node-
positive patients, adjuvant therapy was significantly associated with
improved overall survival (p = 0.004) on univariate analysis.
Narang et al. Radiation Oncology 2011, 6:126
http://www.ro-journal.com/content/6/1/126
Page 7 of 11survival when compared to surgery (mOS: 39.9 vs. 40.1
months, p-0.839), as summarized in Table 2 and illu-
strated in Figure 1. This lack of survival benefit is likely
a result of the imbalance in adverse prognostic factors
between treatment groups. In this series, nodal metasta-
sis (p < 0.001), advanced T stage (p = 0.002), and poorly
differentiated histology (p = 0.011) were all significantly
associated with decreased survival. While margin status
was not a predictor of survival (p = 0.493), margin sta-
tus is widely considered to be a poor prognostic factor,
and its lack of association with survival in this study
m a yb ea t t r i b u t a b l et ot h es m a l ln u m b e ro fp a t i e n t s
w i t hc l o s eo rp o s i t i v em a r g i n s( n=3 ) .R e g a r d l e s s ,t h e
cohort that received CRT had a significantly higher
proportion of patients with advanced T-stage (p =
0.002), pathologic lymph node involvement (p < 0.001),
and positive surgical margins (p = 0.019), and a border-
line statistically significant trend towards poorer histolo-
gic grade (p = 0.053). The fact that survival was
comparable between treatment groups despite these dis-
crepancies suggests the potential benefit of adjuvant
CRT, particularly amongst high risk populations.
Moreover, when baseline demographic and treatment-
related characteristics were adjusted for on multivariate
analysis, a significant association between adjuvant ther-
apy and improved survival appeared. Indeed, this study
represents the second reported survival benefit from
adjuvant CRT found on multivariate analysis, albeit with
a much larger cohort than was analyzed in the afore-
mentioned study by Lee et al [33]. Interestingly, when
patients were stratified by baseline demographic and dis-
ease-related characteristics, no subgroup showed a sig-
nificant survival benefit from adjuvant CRT except for
patients with nodal metastasis, who experienced a large
difference in median survival (mOS: 32.1 vs. 17.5
months, p = 0.004). As suggested in multiple previous
studies, node-positive patients were found to carry a
very poor prognosis on both univariate analysis (p <
0.001) and multivariate analysis (p < 0.001), with a med-
ian survival of only 18.4 months. The fact that node-
positive patients who were not treated with adjuvant
CRT showed a dismal 5-year survival rate of only 5.9%
indicates that this group may be particularly suited for
post-operative therapy. Moreover, while the effect of
adjuvant therapy in node negative patients did not reach
statistical significance, the absolute difference in survival
(mOS: 103.2 vs. 61.6 months) is noteworthy and remi-
niscent of the CONKO-001 trial in which node negative
pancreatic cancer patients experienced superior survival
with adjuvant chemotherapy [34].
While good local control was achieved in this study,
nearly a third of patients suffered from distant relapse,
and roughly 90% of recurrences were attributable in
part to metastatic disease. Consistent with the literature,
the most common sites of metastasis were the liver and
peritoneum. Overall, progression of disease led to more
than half of the deaths in the cohort, with nearly one
third of patients who died harboring disease in the liver.
The prevalence of metastatic disease suggests the need
f o rm o r ee f f e c t i v es y s t e m i ct h e r a p y ,p a r t i c u l a r l yi nh i g h
risk patients. Unfortunately, there is even less
Table 4 Multivariate Cox Proportional Hazards Survival
Analysis of Adjuvant Chemoradiation therapy and
Overall Survival
RR (95% CI) P-value
Age, yrs
< 75 1.00 0.755
≥ 75 0.93 (0.57 - 1.50)
Gender
Female 1.00 0.402
Male 0.84 (0.56-1.26)
Institution
Mayo 1.00 0.222
Hopkins 1.30 (0.85-1.99)
Tumor Stage
T1/T2 1.00 0.317
T3/T4 1.24 (0.81-1.91)
Tumor Size
≤ 3 cm 1.00 0.391
> 3 cm 1.20 (0.79-1.80)
Node
Negative 1.00 <0.001
Positive 4.29 (2.5-7.17)
Histology
Grade 1/2 1.00 0.191
Grade 3 1.35 (0.86-2.41)
Adjuvant Treatment
Observation 1.00 <0.001
Adjuvant CRT* 0.41 (0.25 - 0.67)
*CRT = chemoradiation
Table 5 Initial Sites of First Recurrence by Treatment Group
No Recurrence Local Recurrence Distant Recurrence Local & Distant Overall Recurrences Total Patients
CRT 31 (47.0%) 1 (1.5%) 23 (34.8%) 11 (16.7%) 35 (53.0%) 66
No CRT 86 (71.7%) 6 (5.0%) 26 (21.7%) 2 (1.7%) 34 (28.3%) 120
Total 118 (63.4%) 7 (3.8%) 49 (26.3%) 12 (6.5%) 68 (36.6%) 186
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chemotherapeutic agents when incorporated with radia-
tion for ampullary cancer. Furthermore, the role of adju-
vant chemotherapy alone is an area that has been largely
understudied, a remnant of borrowed U.S. practice pat-
terns supporting adjuvant CRT for resected pancreatic
cancer. A Japanese study of adjuvant mitomycin C and
5-FU for pancreaticobiliary carcinomas found no overall
or disease-free survival benefit in a subset of 24 patients
with ampullary carcinoma when compared to surgery
alone [35]. More recent and robust results from the
European Study Group for Pancreatic Cancer (ESPAC) -
3(v2) trial also showed no difference in survival in 304
patients with resected ampullary cancer who were ran-
domized to 5-FU/folinic acid, gemcitabine, or observa-
tion [36]. Combination chemotherapy may provide
better results, as a randomized control trial comparing
gemcitabine and cisplatin versus gemcitabine alone in
410 patients with locally advanced or metastatic biliary
or ampullary cancers did show superior survival with
the combination regimen (mOS: 11.7 vs. 8.1 months, p
< 0.001), although it should be acknowledged that only
5% of tumors in the study had an ampullary origin [37].
Of note, no study has directly compared adjuvant che-
motherapy alone with adjuvant chemoradiation.
Given the retrospective nature of this study and wide
time period over which this study spanned, our findings
are limited by the variability in treatment regimens and
the potentially unequal distribution of confounding fac-
tors in patient selection between treatment groups. Cer-
tainly, patients in our study were subject to different
operative methods, radiation plans, and chemotherapeu-
t i ca g e n t s ,w h i c hw ew e r eu n a b l et oc o n t r o lf o rd u et o
incomplete information or insufficient power. Addition-
ally, this study has shown that patients selected for adju-
vant CRT at the Johns Hopkins Hospital and the Mayo
Clinic possessed more adverse prognostic factors than
those treated with surgery alone. While several high risk
characteristics were adjusted for in our analysis, other
variables that were not taken into account include per-
formance status and weight loss, both of which may be
correlated with disease outcomes. Since patients who
received adjuvant CRT were significantly younger, it is
easy to imagine that healthier patients were more likely
offered adjuvant treatment. The retrospective nature of
our study may have also compromised our ability to
accurately capture certain information such as the toxi-
city data, which was lower when compared to prior
experience [14]. Furthermore, variations in institutional
protocols regarding treatment delivery can be a source
of bias in studies analyzing data from multiple sites, but
it should be noted that while the distribution of treat-
ment type did in fact vary by institution, there was no
association between institution and survival on univari-
ate or multivariate analysis, and institution did not affect
outcomes when stratified by treatment type. Another
limitation was the number of patients excluded for
either missing data (i.e. stage or nodal status) or because
they were lost to follow-up. It is probable that follow-up
was not consistent among treatment groups, with
patients receiving adjuvant therapy likely showing better
follow-up. The number of patients lost to follow along
w i t ht h en u m b e ro fp a t i e n t sa l i v ea tt i m eo fa n a l y s i s
resulted in a low number of documented recurrences.
Ideally, we would have been able to examine the asso-
ciation between adjuvant therapy and patterns of recur-
rence, but the low number of recurrences prevented the
possibility of meaningful analysis. Nevertheless, this
study combines the experience of two high volume insti-
tutions to allow for the largest series to date that has
examined the role of adjuvant therapy following surgery
for ampullary cancer.
Conclusions
Lymph node involvement, advanced tumor stage, and
poor histology are adverse prognostic factors associated
with poor survival in patients with ampullary carcinoma.
The addition of adjuvant chemoradiation likely improves
survival in patients with high risk disease, particularly in
those with lymph node involvement. Whether all
patients with resectable ampullary carcinoma should be
treated with adjuvant chemoradiation is subject to
debate. Certainly, better systemic therapy is necessary to
improve the high rate of distant metastasis found in this
population.
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